ProCE Banner Activity

当代 HIV 管理:在病毒学抑制患者中调整 ART

Slideset Download
下载此由专家制作的幻灯片集,以查看有关评估病毒学失败的指南和关键数据、针对治疗失败的多类耐药患者的当前管理选择,以及在潜在耐药患者中转换 ART 的考虑因素。

Released: January 21, 2022

Expiration: January 20, 2023

No longer available for credit.

Share

Faculty

Joseph J. Eron

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Princy N. Kumar

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

教育补助金提供者

ViiV Healthcare

Faculty Disclosure

Primary Author

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr.(医学博士)透露,他已收到 Gilead Sciences、Janssen、Merck 和 ViiV Healthcare 的咨询费以及来自 Gilead Sciences、Janssen 和 ViiV Healthcare 的研究支持资金。

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Princy N. Kumar(医学博士、FIDSA、MACP)透露,她从 Amgen、Gilead Sciences、GlaxoSmithKline、Merck 和 Theratechnologies 公司获得了咨询费,从 Gilead Sciences、GlaxoSmithKline、Merck 和 Theratechnologies 公司获得了研究资助金,并在 Gilead Sciences、GlaxoSmithKline、Johnson & Johnson、Merck 和 Pfizer 拥有所有者权益。